| |
| |
|
| Insider
Information: |
Spiegel Robert J. |
| Relationship: |
Director |
| City: |
Menlo Park |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
300,930 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$744,537 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
300,930 |
|
|
| Total
Value |
$744,537 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Geron Corporation |
GERN |
Director |
2023-12-29 |
164,040 |
2010-07-09 |
0 |
Premium* |
|
|
PTC Therapeutics, Inc. |
PTCT |
Chief Medical Officer |
2015-03-13 |
3,239 |
|
0 |
Premium* |
|
|
PDS Biotechnology Corp |
PDSB |
Director |
2019-03-15 |
48,661 |
2015-10-06 |
0 |
Premium* |
|
|
Sucampo Pharmaceuticals, Inc. |
SCMP |
Director |
2018-02-13 |
0 |
2016-06-02 |
0 |
Premium* |
|
|
Cyclacel Pharmaceuticals Inc |
CYCC |
Director |
2023-06-30 |
39,415 |
2021-06-15 |
0 |
Premium* |
|
|
Athenex, Inc. |
ATNX |
Director |
2023-04-21 |
4,592 |
2022-04-08 |
0 |
Premium* |
|
|
Renovorx, Inc. |
RNXT |
Director |
2024-01-26 |
40,983 |
2024-01-26 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
65 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| PTCT |
PTC Therapeutics, Inc. |
Chief Medical OfficerOfficer |
• – – |
2014-01-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,455 |
|
- |
|
| PTCT |
PTC Therapeutics, Inc. |
Chief Medical Officer |
• – – |
2015-03-13 |
4 |
AS |
$75.10 |
$77,355 |
D/D |
(1,030) |
3,239 |
0 |
- |
|
| PTCT |
PTC Therapeutics, Inc. |
Chief Medical Officer |
• – – |
2014-03-13 |
4 |
S |
$31.75 |
$37,656 |
D/D |
(1,186) |
4,269 |
0 |
- |
|
| PDSB |
PDS Biotechnology Corp |
Director |
– • – |
2015-10-06 |
4 |
A |
$7.91 |
$12,253 |
D/D |
1,549 |
38,661 |
0 |
- |
|
| GERN |
Geron Corporation |
Director |
– • – |
2018-03-29 |
4 |
A |
$0.00 |
$0 |
D/D |
1,691 |
63,481 |
0 |
- |
|
| GERN |
Geron Corporation |
Director |
– • – |
2018-06-29 |
4 |
A |
$0.00 |
$0 |
D/D |
2,095 |
65,576 |
0 |
- |
|
| GERN |
Geron Corporation |
Director |
– • – |
2014-12-31 |
4 |
A |
$0.00 |
$0 |
D/D |
2,212 |
48,739 |
0 |
- |
|
| GERN |
Geron Corporation |
Director |
– • – |
2023-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
2,239 |
157,244 |
0 |
- |
|
| ATNX |
Athenex, Inc. |
Director |
– • – |
2023-04-21 |
4 |
A |
$1.31 |
$3,002 |
D/D |
2,300 |
4,592 |
0 |
- |
|
| CYCC |
Cyclacel Pharmaceuticals ... |
Director |
– • – |
2021-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
2,374 |
2,374 |
0 |
- |
|
| GERN |
Geron Corporation |
Director |
– • – |
2012-12-31 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,500) |
63,838 |
0 |
- |
|
| GERN |
Geron Corporation |
Director |
– • – |
2014-06-30 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,500) |
46,527 |
0 |
- |
|
| GERN |
Geron Corporation |
Director |
– • – |
2017-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
2,595 |
54,500 |
0 |
- |
|
| GERN |
Geron Corporation |
Director |
– • – |
2022-12-30 |
4 |
A |
$0.00 |
$0 |
D/D |
2,970 |
151,693 |
0 |
- |
|
| PDSB |
PDS Biotechnology Corp |
Director |
– • – |
2015-10-06 |
4 |
B |
$11.00 |
$33,000 |
D/D |
3,000 |
37,112 |
2.39 |
- |
|
| GERN |
Geron Corporation |
Director |
– • – |
2013-12-31 |
4 |
A |
$0.00 |
$0 |
D/D |
3,033 |
37,671 |
0 |
- |
|
| GERN |
Geron Corporation |
Director |
– • – |
2022-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
3,071 |
148,723 |
0 |
- |
|
| GERN |
Geron Corporation |
Director |
– • – |
2017-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
3,166 |
51,905 |
0 |
- |
|
| GERN |
Geron Corporation |
Director |
– • – |
2017-09-29 |
4 |
A |
$0.00 |
$0 |
D/D |
3,297 |
57,797 |
0 |
- |
|
| GERN |
Geron Corporation |
Director |
– • – |
2020-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
3,297 |
106,298 |
0 |
- |
|
| GERN |
Geron Corporation |
Director |
– • – |
2023-09-29 |
4 |
A |
$0.00 |
$0 |
D/D |
3,390 |
160,634 |
0 |
- |
|
| GERN |
Geron Corporation |
Director |
– • – |
2023-12-29 |
4 |
A |
$0.00 |
$0 |
D/D |
3,406 |
164,040 |
0 |
- |
|
| ATNX |
Athenex, Inc. |
Director |
– • – |
2022-04-08 |
4 |
A |
$0.75 |
$3,000 |
D/D |
3,989 |
3,989 |
0 |
- |
|
| GERN |
Geron Corporation |
Director |
– • – |
2017-12-29 |
4 |
A |
$0.00 |
$0 |
D/D |
3,993 |
61,790 |
0 |
- |
|
| GERN |
Geron Corporation |
Director |
– • – |
2018-09-28 |
4 |
A |
$0.00 |
$0 |
D/D |
4,084 |
69,660 |
0 |
- |
|
65 Records found
|
|
Page 1 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
